Peritoneal Surface Oncology Group International (PSOGI)’s Post

#RESEARCHSPOTLIGHT New PODCAST alert! The 2022 PSOGI consensus on #HIPEC regimens: HIPEC technologies https://lnkd.in/dfqzycCT Read the manuscript here https://lnkd.in/dB5c7a5h with recommendations on ✅ correct dosimetry of intraperitoneal chemotherapy drugs and their carrier solutions, ✅ the use of heat ✅ the best regimen for each chemotherapy drug used intraperitoneally ✅ safety considerations related to the use of HIPEC In this podcast, Aditi Bhatt from the #PSOGI, discusses the clinical implications of the key results of this section of the consensus with the lead authors kurt Van der Speeten from Ziekenhuis Oost Limberg, Genk, Belgium and Shigeki Kusamura from Istituto Nazionale dei Tumori, Milan Italy. ❓ What is the ideal HIPEC regimen? or can there be an 'ideal HIPEC'? ❓ The best method for performing HIPEC- Closed or Open? ❓ What is best method of calculating the dose of HIPEC drugs? ❓ Should the HIPEC regimen be modified to reduce the morbidity - when and how? ❓ Should there be trials comparing different HIPEC regimens in ovarian cancer? Ideal design for such trials? ❓ Can sodium thiosulfate have a detrimental effect on the efficacy of HIPEC? ❓ What is the ideal temperature for performing HIPEC? And what is the thermal dose equivalent? ❓ Should Oxaliplatin HIPEC be used outside clinical trials? ❓ Should Paclitaxel be used for performing HIPEC? ❓ What can one look forward to in the future- translational research? triple HIPEC? European Society of Surgical Oncology (ESSO) ISSPP e.V. | International Society for the Study of Pleura and Peritoneum European School of Peritoneal Surface Oncology (ESPSO) International Journal of Gynecological Cancer (IJGC)